Key result
Trans-catheter mitral valve-in-valve replacement was successfully performed in a high-risk 39-year-old female using VA-ECMO for haemodynamic support.
Why the study?
Treatment options for bioprosthetic mitral valve failure in patients at high or prohibitive surgical risk are limited, and data on trans-catheter valve placement while on VA-ECMO are scarce.
Case Report (n=1)
Trans-catheter mitral valve-in-valve replacement in a stenotic bioprosthesis is feasible in very high-risk patients using VA-ECMO for hemodynamic support.
No takes yet. Share an insight, caveat, or question.
TMViV on VA-ECMO succeeded in one prohibitive-risk patient; hypothesis-generating and requires prospective validation before wider use.
Bainiwal et al. (2023) conducted a case report in Severe bioprosthetic mitral valve stenosis (n=1). Trans-catheter mitral valve-in-valve (TMViV) replacement on VA-ECMO was evaluated on Procedural success and clinical recovery. Trans-catheter mitral valve-in-valve replacement was successfully performed in a high-risk 39-year-old female using VA-ECMO for haemodynamic support.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: